We made this switch because KCa2.2 is the most abundantly expressed KCa2 channel in the mammalian CNS (Adelman et al., 2012) and therefore constitutes an attractive target for the treatment of ataxia and epilepsy. The gene discussed is KCNN2; the disease is cerebellar ataxia.